Aptorum Group Ltd Class A (APM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Aptorum Group Ltd Class A (APM) has a cash flow conversion efficiency ratio of -0.039x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-535.72K) by net assets ($13.79 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Aptorum Group Ltd Class A (APM) liquidity interval to measure how many days the company can operate on defensive assets alone.
Aptorum Group Ltd Class A - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Aptorum Group Ltd Class A's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Aptorum Group Ltd Class A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aptorum Group Ltd Class A ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Modern Times Group Mtg AB
ST:MTG-A
|
0.079x |
|
GEOTRANS S.A. ZY -10
F:5Z4
|
-0.018x |
|
Bioatla Inc
NASDAQ:BCAB
|
0.141x |
|
Silver Bull Resources Inc
TO:SVB
|
0.022x |
|
Beauce Gold Fields Inc
V:BGF
|
-0.059x |
|
Digistar Corporation Bhd
KLSE:0029
|
-0.152x |
|
Computer Forms (Malaysia) Bhd
KLSE:8044
|
-0.017x |
|
K.C. Metalsheet Public Company Limited
BK:KCM
|
0.042x |
Annual Cash Flow Conversion Efficiency for Aptorum Group Ltd Class A (2016–2025)
The table below shows the annual cash flow conversion efficiency of Aptorum Group Ltd Class A from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see Aptorum Group Ltd Class A stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $13.79 Million | $-1.84 Million | -0.133x | -31.63% |
| 2024-12-31 | $11.78 Million | $-1.19 Million | -0.101x | +79.86% |
| 2023-12-31 | $15.38 Million | $-7.72 Million | -0.502x | +68.07% |
| 2022-12-31 | $7.83 Million | $-12.32 Million | -1.573x | -87.90% |
| 2021-12-31 | $17.51 Million | $-14.65 Million | -0.837x | -100.42% |
| 2020-12-31 | $38.15 Million | $-15.93 Million | -0.418x | +53.66% |
| 2019-12-31 | $14.85 Million | $-13.38 Million | -0.901x | -194.02% |
| 2018-12-31 | $32.75 Million | $-10.04 Million | -0.306x | -60.21% |
| 2017-12-31 | $30.23 Million | $-5.78 Million | -0.191x | -74.34% |
| 2016-12-31 | $25.11 Million | $-2.76 Million | -0.110x | -- |
About Aptorum Group Ltd Class A
Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small mol… Read more